Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P970003/S251

VNS Therapy Model 3100 Programmer, VNS Therapy Model 2000 Programming Wand

LivaNova USA, Inc. · Decision date Nov 25, 2025

FDA DECISIONP970003/S251

What did the FDA approve?

FDA records P970003/S251 as a supplement to PMA P970003, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Nov 25, 2025.

FDA approval order statement

approval for a new version of the M3100 v2.0 Clinician Programmer update, including a new Pause Therapy function, new version of the M2000 v1.1.3.0 Wand, and updates to the Digital Product Platform
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Neurology
Decision date
Nov 25, 2025
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P970003/S251
Regulatory pathway
PMA supplement
Product code
LYJ
Decision code
APPR
Decision date
Nov 25, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stimulator, autonomic nerve, implanted for epilepsy.

Product code
LYJ
FDA device class
3

For the original device and its historical approval scope, see PMA P970003. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P970003 · Original PMA

    VNS THERAPY SYSTEM

  2. P970003/S251 received

    Application receipt date recorded by FDA.

  3. P970003/S251 · FDA decision

    Real-Time Process

Timeline entries are records held by MedtechLedger for P970003. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P970003

Product / regulatory recordCompanyPathwayDecision dateSource
LivaNova USA, Inc.PMA approvalJul 16, 1997FDA
VNS Therapy SystemP970003/S248
LivaNova USA, Inc.PMA supplementSep 5, 2025FDA
VNS Therapy SystemP970003/S250
LivaNova USA, Inc.PMA supplementSep 12, 2025FDA
VNS THERAPY SYSTEMP970003/S252
LivaNova USA, Inc.PMA supplementDec 17, 2025FDA
VNS Therapy SystemP970003/S253
LivaNova USA, Inc.PMA supplementMar 4, 2026FDA
VNS Therapy SystemP970003/S249
LivaNova USA, Inc.PMA supplementAug 12, 2026FDA
VNS Therapy SystemP970003/S254
LivaNova USA, Inc.PMA supplementOct 2, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

LivaNova USA, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
100 Cyberonics Blvd., Houston, TX, 77058

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records